BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue

MT Newswires Live

02/17

BriaCell Therapeutics (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.

The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.

The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612452720"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612452720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612452720?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612452720","market":"fut","top_or_hot":-1,"title":"BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue","media":"MT Newswires Live","content":"<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.</p><p>The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.</p><p>The trial is being conducted under a US Food and Drug Administration '<a href=\"https://laohu8.com/S/FTRK\">Fast Track</a>' designation, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-17 21:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.</p><p>The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.</p><p>The trial is being conducted under a US Food and Drug Administration '<a href=\"https://laohu8.com/S/FTRK\">Fast Track</a>' designation, the company said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCTX","symbol_name":"BriaCell Therapeutics Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612452720","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612452720","pubTimestamp":1771334096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BriaCell Therapeutics  said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCTX":"BriaCell Therapeutics Corp.","BK4139":"生物科技"},"translate_title":"BriaCell Therapeutics的3期乳腺癌治疗试验获得第五次DSMB建议继续进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCTX":1.5},"content_text":"BriaCell Therapeutics (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}